<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3048">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337424</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0170</org_study_id>
    <nct_id>NCT04337424</nct_id>
  </id_info>
  <brief_title>Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2</brief_title>
  <acronym>EasyCoV</acronym>
  <official_title>Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>societe SkillCell - 97198 Jarry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CNRS Alcediag UMR9005 - societe Sys2Diag - 34184 Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronavirus disease 2019 or COVID-19 is a highly contagious infectious disease. Symptoms of&#xD;
      the disease are non-specific (fever, cough, dyspnea and fatigue), common with many seasonal&#xD;
      viruses, which complicates the diagnosis. For mild forms, which represent the vast majority&#xD;
      of cases, hospitalization is not necessary and treatment is symptomatic. However in more&#xD;
      severe cases, hospitalization is required and sometimes even admission to an intensive care&#xD;
      unit.&#xD;
&#xD;
      Several diagnostic tests are already available, but they require, in all cases, the&#xD;
      intervention of qualified health personnel to carry out the sample, which includes a risk of&#xD;
      contagion and an expensive and time-consuming laboratory analysis and reagents. These tests&#xD;
      are therefore not very suitable for massive screenings.&#xD;
&#xD;
      We want to evaluate the performance of a detection test performed on a salivary sample in the&#xD;
      diagnosis of SARS-CoV-2. This test will be non-invasive, performed without any analytical&#xD;
      device and will restore its qualitative result &quot;infected versus non-infected&quot; in less than 1&#xD;
      hour (30min objective).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study taking place at the Montpellier University Hospital, comparing a salivary sample group&#xD;
      with active infection (participants) for SARS-COV2 with a salavary sample tested negative&#xD;
      (cured, convalescent and negative) for SARS-COV2 (healthcare workers ,participants)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 13, 2020</start_date>
  <completion_date type="Actual">October 7, 2020</completion_date>
  <primary_completion_date type="Actual">October 7, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Specific detection of SARS-CoV-2 specific RNA</measure>
    <time_frame>1 day</time_frame>
    <description>Detection by the LAMP method is to be corroborated with the reference method, RT-PCR on the same salivary sample. Only one sample is taken per subject participating in the study. The sample is divided into two aliquots which will be analyzed by LAMP and RT-PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analytical sensitivity of the LAMP test.</measure>
    <time_frame>1 day</time_frame>
    <description>This test developed by SYS2DIAG / SKILLCELL must be able to detect a minimum viral load equivalent to that of the standard method on the same salivary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation between the measurement of the assayed viral load (CT value) by the standard method and by the LAMP developed by SYS2DIAG / SKILLCELL.</measure>
    <time_frame>1 day</time_frame>
    <description>A correlation between the viral loads measured on the same sample by RT-PCR and by LAMP will be carried out.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the use of saliva samples compared to nasopharyngeal samples</measure>
    <time_frame>1 day</time_frame>
    <description>The RT-PCR results on these 2 types of samples and the LAMP results for the saliva samples will be compared with the patient diagnosis to assess the feasibility and performance of the saliva samples for the molecular diagnosis of SARS-CoV-2.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">627</enrollment>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Participants with active infection test to SARS-COV2</arm_group_label>
    <description>Sampling of saliva (1 to 2 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Convalescent participants for SARS-COV2</arm_group_label>
    <description>Sampling of saliva (1 to 2 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants cured to SARS-COV2</arm_group_label>
    <description>Sampling of saliva (1 to 2 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with negative test to SARS-COV2</arm_group_label>
    <description>Sampling of saliva (1 to 2 ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sampling salivary</intervention_name>
    <description>Collection of 1 to 2 ml of saliva</description>
    <arm_group_label>Convalescent participants for SARS-COV2</arm_group_label>
    <arm_group_label>Participants cured to SARS-COV2</arm_group_label>
    <arm_group_label>Participants with active infection test to SARS-COV2</arm_group_label>
    <arm_group_label>Participants with negative test to SARS-COV2</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Salivary sampling (1 to 2 ml of salivary)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The samples size is 90 samples with active infection to SARS-COV2 and at least 90 with no&#xD;
        active infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Control subjects (COV2- group): Participants ( Healthcare staff, patients and DRIVE&#xD;
        participants) negative for SARS-CoV-2&#xD;
&#xD;
        - Infected subjects (COV2 + group): Patients diagnosed positive for SARS-CoV-2 hospital&#xD;
        staff known to be positive and coming to do a control PCR DRIVE participants.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eligibility Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        - Control subjects (COV2- group): Healthcare staff presumed and diagnosed negative for&#xD;
        SARS-CoV-2&#xD;
&#xD;
        - Infected subjects (COV2 + group): Patients diagnosed positive for SARS-CoV-2 hospital&#xD;
        staff known to be positive and coming to do a control PCR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not affiliated with a French Social Security Systemscheme or equivalent system&#xD;
&#xD;
          -  Persons deprived of their liberty, adult protected under guardianship or vulnerable&#xD;
             persons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>REYNES Jacques, PU PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montpellier Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 5, 2020</study_first_submitted>
  <study_first_submitted_qc>April 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diagnosis test</keyword>
  <keyword>Salivary sampling</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

